Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol

Journals

1. Lynch H, Nustas R, Kassim T, Snyder C, Shaw T, Diab O. The benefits of a model of interval comprehensive assessments (MICA) in hereditary cancer Syndromes: Hereditary diffuse gastric cancer (HDGC) as an example. Cancer Genetics 2019;233-234:43 View
2. Frey M, Kahn R, Chapman-Davis E, Tubito F, Pires M, Christos P, Anderson S, Mukherjee S, Jordan B, Blank S, Caputo T, Sharaf R, Offit K, Holcomb K, Lipkin S. Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling. Journal of Clinical Oncology 2020;38(13):1389 View
3. Rutgers E, Balmana J, Beishon M, Benn K, Evans D, Mansel R, Pharoah P, Perry Skinner V, Stoppa-Lyonnet D, Travado L, Wyld L. European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer. European Journal of Cancer 2019;106:45 View
4. Menko F, Jeanson K, Bleiker E, van Tiggelen C, Hogervorst F, ter Stege J, Ait Moha D, van der Kolk L. The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure. European Journal of Human Genetics 2020;28(8):1020 View
5. Menko F, ter Stege J, van der Kolk L, Jeanson K, Schats W, Moha D, Bleiker E. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Familial Cancer 2019;18(1):127 View
6. Reid S, Spalluto L, Pal T. Strategies to enhance identification of hereditary breast cancer gene carriers. Expert Review of Molecular Diagnostics 2020;20(9):861 View
7. Dean M, Tezak A, Johnson S, Pierce J, Weidner A, Clouse K, Pal T, Cragun D. Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers. Patient Education and Counseling 2021;104(4):720 View
8. Cragun D, Weidner A, Tezak A, Clouse K, Pal T. Family communication of genetic test results among women with inherited breast cancer genes. Journal of Genetic Counseling 2021;30(3):701 View
9. Nitecki R, Moss H, Watson C, Urbauer D, Melamed A, Lu K, Lipkin S, Offit K, Rauh-Hain J, Frey M. Facilitated cascade testing (FaCT): a randomized controlled trial. International Journal of Gynecologic Cancer 2021;31(5):779 View
10. Kaphingst K, Kohlmann W, Chambers R, Goodman M, Bradshaw R, Chan P, Chavez-Yenter D, Colonna S, Espinel W, Everett J, Gammon A, Goldberg E, Gonzalez J, Hagerty K, Hess R, Kehoe K, Kessler C, Kimball K, Loomis S, Martinez T, Monahan R, Schiffman J, Temares D, Tobik K, Wetter D, Mann D, Kawamoto K, Del Fiol G, Buys S, Ginsburg O. Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. BMC Health Services Research 2021;21(1) View
11. Kim S, Aceti M, Baroutsou V, Bürki N, Caiata-Zufferey M, Cattaneo M, Chappuis P, Ciorba F, Graffeo-Galbiati R, Heinzelmann-Schwarz V, Jeong J, Jung M, Kim S, Kim J, Lim M, Ming C, Monnerat C, Park H, Park S, Pedrazzani C, Rabaglio M, Ryu J, Saccilotto R, Wieser S, Zürrer-Härdi U, Katapodi M. Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study. JMIR Research Protocols 2021;10(6):e26264 View
12. Baroutsou V, Cerqueira Gonzalez Pena R, Schweighoffer R, Caiata-Zufferey M, Kim S, Hesse-Biber S, Ciorba F, Lauer G, Katapodi M. Predicting Openness of Communication in Families With Hereditary Breast and Ovarian Cancer Syndrome: Natural Language Processing Analysis. JMIR Formative Research 2023;7:e38399 View
13. Frey M, Finch A, Kulkarni A, Akbari M, Chapman-Davis E. Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing. American Society of Clinical Oncology Educational Book 2022;(42):471 View
14. Bommer C, Lupatsch J, Bürki N, Schwenkglenks M. Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. The European Journal of Health Economics 2022;23(5):807 View
15. Sarki M, Ming C, Aceti M, Fink G, Aissaoui S, Bürki N, Graffeo R, Heinimann K, Caiata Zufferey M, Monnerat C, Rabaglio M, Zürrer-Härdi U, Chappuis P, Katapodi M. Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort. Journal of Personalized Medicine 2022;12(10):1740 View
16. Frey M, Ahsan M, Bergeron H, Lin J, Li X, Fowlkes R, Narayan P, Nitecki R, Rauh-Hain J, Moss H, Baltich Nelson B, Thomas C, Christos P, Hamilton J, Chapman-Davis E, Cantillo E, Holcomb K, Kurian A, Lipkin S, Offit K, Sharaf R. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis. Journal of Clinical Oncology 2022;40(35):4129 View
17. Pedrazzani C, Aceti M, Schweighoffer R, Kaiser-Grolimund A, Bürki N, Chappuis P, Graffeo R, Monnerat C, Pagani O, Rabaglio M, Katapodi M, Caiata-Zufferey M. The Communication Chain of Genetic Risk: Analyses of Narrative Data Exploring Proband–Provider and Proband–Family Communication in Hereditary Breast and Ovarian Cancer. Journal of Personalized Medicine 2022;12(8):1249 View
18. Kahn R, Ahsan M, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain J, Fowlkes R, Tubito F, Pires M, Christos P, Tkachuk K, Krinsky H, Sharaf R, Offit K, Lipkin S, Frey M. Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?. Familial Cancer 2023;22(2):127 View
19. Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis P, Kohler C, Erlanger T, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse L, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands E, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi M. Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. Public Health Genomics 2018;21(3-4):121 View
20. Frey M, Ahsan M, Badiner N, Lin J, Narayan P, Nitecki R, Rauh‐Hain J, Moss H, Fowlkes R, Thomas C, Bergeron H, Christos P, Levi S, Blank S, Holcomb K, Cantillo E, Sharaf R, Lipkin S, Offit K, Chapman‐Davis E. What happens in the long term: Uptake of cancer surveillance and prevention strategies among at‐risk relatives with pathogenic variants detected via cascade testing. Cancer 2022;128(24):4241 View
21. Sarki M, Ming C, Aissaoui S, Bürki N, Caiata-Zufferey M, Erlanger T, Graffeo-Galbiati R, Heinimann K, Heinzelmann-Schwarz V, Monnerat C, Probst-Hensch N, Rabaglio M, Zürrer-Härdi U, Chappuis P, Katapodi M. Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort. Cancers 2022;14(7):1636 View
22. Pedrazzani C, Ming C, Bürki N, Caiata-Zufferey M, Chappuis P, Duquette D, Heinimann K, Heinzelmann-Schwarz V, Graffeo-Galbiati R, Merajver S, Milliron K, Monnerat C, Pagani O, Rabaglio M, Katapodi M. Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years. Cancers 2021;13(24):6254 View
23. Barnoy S, Dagan E, Kim S, Caiata-Zufferey M, Katapodi M. Privacy and utility of genetic testing in families with hereditary cancer syndromes living in three countries: the international cascade genetic screening experience. Frontiers in Genetics 2023;14 View
24. Baroutsou V, Duong V, Signorini A, Saccilotto R, Ciorba F, Bürki N, Caiata-Zufferey M, Ryu J, Kim S, Lim M, Monnerat C, Zürrer-Härdi U, Kim J, Heinimann K, Graffeo R, Park J, Rabaglio M, Chappuis P, Kim S, Katapodi M. Acceptability and Usability of the Family Gene Toolkit for Swiss and Korean Families Harboring BRCA1/BRAC2 Pathogenic Variants: A Web-Based Platform for Cascade Genetic Testing. Cancers 2023;15(18):4485 View
25. Joder C, Gmür A, Solass W, Christe L, Rabaglio M, Fluri M, Rau T, Saner F, Knabben L, Imboden S, Mueller M, Siegenthaler F. Real-World Data on Institutional Implementation of Screening for Mismatch Repair Deficiency and Lynch Syndrome in Endometrial Cancer Patients. Cancers 2024;16(3):671 View
26. Aceti M, Caiata-Zufferey M, Pedrazzani C, Schweighoffer R, Kim S, Baroutsou V, Katapodi M, Kim S. Modes of responsibility in disclosing cancer genetic test results to relatives: An analysis of Swiss and Korean narrative data. Patient Education and Counseling 2024;123:108202 View
27. Diez de los Rios de la Serna C, Dowling M, McNamara N, Ivory J, Hanhauser Y, Murphy M, Dean M. A scoping review of parents’ disclosure of BRCA1/2 genetic alteration test results to underage children. Patient Education and Counseling 2025;131:108561 View

Books/Policy Documents

1. . Constitutional Oncogenetics. View